Semaglutide injections reversed some cases of MASH liver disease in clinical trials, reducing inflammation in 62.9% of ...

More than half of adults with MASH receiving semaglutide had resolution of steatohepatitis at 72 weeks. A reduction in liver fibrosis stage was observed among 36.8% of the semaglutide group.

Adult patients with metabolic dysfunction–associated steatohepatitis (MASH) and moderate or advanced liver fibrosis showed improved liver histology with a once-weekly dose of semaglutide (Wegovy ...

Semaglutide and similar GLP-1 drugs are poised to become frontline treatments for a severe form of liver disease.

An international study reveals that the drug can reverse liver damage in patients. An international study led by researchers ...

An SGLT2 inhibitor helped improve metabolic dysfunction-associated steatohepatitis (MASH) in people with or without type 2 ...

This is the first regulatory-level trial showing the benefit of semaglutide for people with MASH. The trial is led by two chief investigators, Professor Philip Newsome at King's College London and ...

Semaglutide significantly improved liver fibrosis and steatohepatitis resolution in MASH patients over 72 weeks compared to placebo. The study involved 800 patients receiving semaglutide and 400 ...

In a new study, semaglutide reduced liver fat, inflammation, and scarring in people with MASH. Patients also saw improvements in weight, blood sugar, and insulin resistance. Experts say ...

The study participants reflected a diverse population of MASH patients. About 56% had type 2 diabetes, and approximately 73% were classified as obese. This suggests that semaglutide may be ...